| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2026-011 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | 注2：收益金额为四舍五入保留两位小数后的结果。 二、截至本公告日，公司最近十二个月使用募集资金进行现金管 上海海顺新型药用包装材料股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 第五届董事会第三十五次会议和第五届监事会第二十三次会议，审议 通过了《关于继续使用部分闲置募集资金进行现金管理的议案》，同 意延长可转换公司债券部分闲置募集资金进行现金管理的授权期限， 继续使用不超过人民币22,000万元的可转换公司债券部分闲置募集 资金进行现金管理。使用期限为自原到期之日即2025年4月10日起12 个月内进行滚动使用。除此之外，关于使用可转换公司债券闲置募集 资金进行现金管理的其他事宜保持不变。具体内容详见2025年3月27 日刊登在巨潮资讯网（http:/ ...

2026年1月，公司签署了股权转让补充协议，支付条款涉及未来安排，第一期付款在条件满足后7日内支 付，第二期在交割日后4个月内支付，需跟踪后续进展。 产品研发进展 公司高性能医用膜材等新产品处于研发阶段，同时绿色包装政策推进可能带来业务增量，值得留意相关 动态。 经济观察网海顺新材(300501)在2026年有以下值得关注的事件或动态，可能影响公司未来经营或市场表 现。 业绩经营情况 公司需关注2026年季度财报的发布，以验证营收增长和成本控制效果，这可能缓解估值压力。 关联交易进展 以上内容基于公开资料整理，不构成投资建议。 经济观察网海顺新材(300501)在2026年有以下值得关注的事件或动态，可能影响公司未来经营或市场表 现。 业绩经营情况 公司需关注2026年季度财报的发布，以验证营收增长和成本控制效果，这可能缓解估值压力。 关联交易进展 2026年1月，公司签署了股权转让补充协议，支付条款涉及未来安排，第一期付款在条件满足后7日内支 付，第二期在交割日后4个月内支付，需跟踪后续进展。 产品研发进展 公司高性能医用膜材等新产品处于研发阶段，同时绿色包装政策推进可能带来业务增量，值得留意相关 动态。 ...

证券代码：300501 证券简称：海顺新材 公告编号：2026-010 债券代码：123183 债券简称：海顺转债 上海海顺新型药用包装材料股份有限公司 关于全资子公司及孙公司变更法定代表人 并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于近日收到全资子公司上海莘砖企业管理有限公司、孙公司上海法福 德包装科技有限公司的通知，法定代表人变更为"黄勤"，上述变更 事项已完成工商登记手续并取得新换发的《营业执照》，具体情况如 下： 一、变更后的营业执照信息 （一）上海莘砖企业管理有限公司 名称：上海莘砖企业管理有限公司 统一社会信用代码：91310117MADKBJ0R1E 类型：有限责任公司(自然人投资或控股的法人独资) 法定代表人：黄勤 成立日期：2024 年 5 月 7 日 注册地址：上海市松江区洞泾镇莘砖公路 3456 弄 1 号 705 室 注册资本：500 万人民币 经营范围：一般项目：企业管理咨询；非居住房地产租赁；物业 管理；停车场服务；会议及展览服务；市场营销策划；咨 ...

证券代码：300501 证券简称：海顺新材 公告编号：2026-009 债券代码：123183 债券简称：海顺转债 上海海顺新型药用包装材料股份有限公司 关于孙公司变更法定代表人并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于近日收到孙公司苏州海顺光电科技有限公司的通知，法定代表人由 "林武辉"变更为"黄勤"，上述变更事项已完成工商登记手续并取 得新换发的《营业执照》，具体情况如下： 一、变更后的营业执照信息 成立日期：2021 年 11 月 30 日 住所：苏州市吴江区东太湖生态旅游度假区（太湖新城）八坼白 龙桥村 4 组 注册资本：650 万人民币 经营范围：一般项目：光电子器件制造；光电子器件销售；电子 专用材料制造；电子专用材料研发；电子专用材料销售；医用包装材 料制造；包装材料及制品销售；高性能纤维及复合材料制造；高性能 纤维及复合材料销售；新材料技术研发；橡胶制品制造；橡胶制品销 售；塑料制品制造；塑料制品销售；货物进出口；技术进出口；技术 服务、技术开发、技术咨询、 ...

Core Viewpoint - The company, HaiShun New Materials (300501), has announced an expected net profit for 2025 that will significantly decline compared to the previous year, indicating a challenging financial outlook ahead [1]. Financial Performance - The company projects a net profit attributable to shareholders of the listed company to be between -25 million to -18 million yuan for 2025 [1]. - This represents a decline of 133.52% to 124.13% compared to the previous year's net profit of 74.59 million yuan [1].

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

Core Viewpoint - The company, Haishun New Materials (300501.SZ), is forecasting a net loss of between 18 million to 25 million yuan for the year 2025, a significant decline from a profit of 74.59 million yuan in the same period last year [1] Financial Performance - The expected non-recurring net loss for 2025 is projected to be between 39 million to 50 million yuan, compared to a profit of 69.62 million yuan in the previous year [1] - The decline in performance is attributed to a decrease in gross margin, as the company adopts a market price strategy to expand its market presence [1] Cost Factors - The company has seen a significant increase in fixed assets over the past year, leading to a higher depreciation expense that has notably raised operating costs compared to the same period last year [1] - The company recorded a loss of over 38 million yuan from the impairment of a 43.015% stake in Shanghai Jiucheng Packaging Co., Ltd. during the reporting period [1] Revenue Impact - Interest income has decreased by over 10 million yuan during the reporting period [1] - The implementation of an employee stock ownership plan has resulted in an increase of approximately 10 million yuan in stock incentive expenses [1]

海顺新材公告，预计2025年度净利润为亏损1800万元至2500万元，同比下降124.13%至133.52%。本报 告期毛利率有所下降，一方面公司积极采取贴近市场价格的策略拓展市场；另一方面，公司近一年多固 定资产增加较多，本报告期相对去年同期计提折旧额增加，显著推高营业成本；公司出售上海久诚包装 有限公司43.015%股权，计提减值损失3800余万元；公司利息收入减少1000余万元；公司实施员工持股 计划，导致股权激励费用增加了约1000万元。 ...

Financial Performance - The company expects a net profit of -25 million yuan for the year 2025, representing a decline of 133.52% compared to the previous year[6] - The net profit after deducting non-recurring gains and losses is projected to be -50 million yuan, a decrease of 171.82% year-over-year[6] - The decline in gross margin is attributed to a market pricing strategy and increased depreciation costs due to significant fixed asset additions over the past year[8] - The company recorded a impairment loss of over 38 million yuan from the sale of a 43.015% stake in Shanghai Jiucheng Packaging Co., Ltd.[8] - Interest income decreased by over 10 million yuan during the reporting period[8] - The implementation of an employee stock ownership plan resulted in an increase of approximately 10 million yuan in equity incentive expenses[8] Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm[7] - Detailed financial data will be disclosed in the company's 2025 annual report[9] - The performance forecast period is from January 1, 2025, to December 31, 2025[4] Investor Guidance - The company advises investors to make cautious decisions and be aware of investment risks[9]

2025 年 12 月 18 日，上海海顺新型药用包装材料股份有限公司 （以下简称"公司"）召开第六届董事会第三次会议，审议通过了《关 于转让参股公司全部股权暨签署<股权转让协议>的议案》，同意将持 有的上海久诚包装有限公司（以下简称"上海久诚"）43.015%股权转 让给凸版利丰雅高（香港）有限公司，交易完成后公司将不再持有上 海久诚的股权。同日，各方签署了《股权转让协议》。具体内容详见 公司于 2025 年 12 月 18 日在巨潮资讯网（www.cninfo.com.cn）披露 的《关于转让参股公司全部股权暨签署<股权转让协议>的公告》（公 告编号：2025-118）。 考虑到本次股权交易转让款涉及跨境收付，为保证合规支付，经 协商一致，2026 年 1 月 13 日，各方签署了《股权转让协议之补充协 议》，对《股权转让协议》5.2 条中约定的支付条款进行了调整。具 体内容详见公司于 2026 年 1 月 15 日在巨潮资讯网（www.cninfo.com. | 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2026-007 | | --- | --- | --- | | 债券代码：12 ...